摘要
新型冠状病毒肺炎(COVID-19)具有高度的传染性,中医药防治COVID-19已经取得显著疗效,以络病学理论为指导的连花清瘟胶囊用于治疗病毒感染相关疾病已有多年历史,因其具有抗病毒、抗炎及免疫调节的作用,已经在国家卫健委和多个省市的诊疗方案中被推荐用于新冠病毒的防治。相关研究表明,连花清瘟胶囊能够抑制SARS-Co V-2的活性、有效改善COVID-19患者的临床症状,文章为防治该病提供了初步的临床研究证据。
COVID-19 has high infectivity,Chinese medicine has been used in the prevention and treatment of COVID-19 and has achieved remarkable curative effect.It has been used in the treatment of virus infection-related diseases for many years under the guidance of the theory of collaterals diseases.Because of its antiviral,anti-inflammatory and immunomodulatory effects,it has been recommended to be used in the prevention and treatment of novel coronavirus in the medical programs of the national health commission and many provinces and cities.Relevant studies have shown that Lianhua Qingwen can inhibit the activity of SARS-Co V-2 and effectively improve the clinical symptoms of COVID-19 patients,providing preliminary clinical research evidence for the prevention and treatment of the disease.
作者
田晓玲
华川
张艳
赵勇
TIAN Xiaoling;HUA Chuan;ZHANG Yan;ZHAO Yong(Clinical College of Traditional Chinese Medicine,Hubei University of Chinese Medicine,Wuhan 430061,Hubei,China;Hubei Provincial Hospital of Traditional Chinese Medicine,Wuhan 430074,Hubei,China)
出处
《辽宁中医药大学学报》
CAS
2020年第8期184-187,共4页
Journal of Liaoning University of Traditional Chinese Medicine
基金
湖北省自然科学基金面上项目(2019CFB800)
中国中医科学院中医基础理论研究所基本科研业务费自主选题项目(YZ-1837)
作者简介
田晓玲(1995-),女(土家族),湖北恩施人,硕士研究生,研究方向:中医药防治内分泌代谢及免疫性疾病的研究;通讯作者:华川(1971-),女,湖北武汉人,主任医师、副教授,硕士研究生导师,博士后,研究方向:中医药防治内分泌代谢及免疫性疾病的研究。E-mail:1132988422@qq.com。
